Saturday, July 11, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
MARKETSFTC Forces John Deere to Open Its Repair Ecosystem — and the Aftermarket Parts Industry WinstodayENERGYOccidental's Carbon Capture Isn't a Climate Bet. It's a Tax Credit Trade.4 weeks agoTRADE & TARIFFSTariff Tailwinds Are Still Running for U.S. Metals — but the Easy Money in Steel and Aluminum May Already Be PricedtodayTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware4 weeks agoTRADE & TARIFFSMcCormick's $28M Tariff Refund Is a One-Time Cushion — the Underlying Cost Pressure Hasn't Gone AwaytodayTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge4 weeks agoENERGYCommonwealth LNG Permit Review Opens — Another Export Terminal in the Queue Benefits the Whole LNG Supply ChaintodayENERGYSLB's Quiet Second Act: How Sanctions Reroute the Oilfield Services Backlog4 weeks agoTECHTrump Accelerates Post-Quantum Encryption Deadlines — and a Handful of Small-Cap Security Firms Are the Direct BeneficiariestodayTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think4 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts Years Off the SMR TimelinetodayENERGYThe FERC Docket Nobody Reads: How Pipeline Certificates Quietly Pick LNG's Winners4 weeks agoDEFENSENATO's 3.5% GDP Spending Push Is a Multi-Year Order Book for U.S. Defense PrimestodayTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron4 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable MarkettodayTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map4 weeks agoHEALTHCARE & FDAMedicare Starts Covering Obesity Drugs — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential CustomerstodayENERGYWhy Williams (WMB) Is Really a Policy Stock, Not a Pipeline Stock4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger MarketyesterdayENERGYDOE Reopens the LNG Export Spigot: Cheniere Cashes In First, Kinder Morgan Collects the Toll4 weeks agoHEALTHCARE & FDAElevance Suing CMS Over Medicare Advantage Stars Is a Warning Sign for the Entire Managed Care SectoryesterdayTECHThe Chip Stack Below the Pentagon's AI Buildup4 weeks agoTECHWhite House Quantum Summit and Accelerated PQC Deadlines Create a Spending Runway for IonQ and IBMyesterdayDEFENSEHII's Mission Technologies: The Unsexy Segment Where Navy Autonomy Dollars Actually Land First4 weeks agoENERGYCommonwealth LNG Permit Review Opens a New Export Capacity Race — Cheniere Holds the Pole PositionyesterdayTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion4 weeks agoCRYPTOSEC's Pending Crypto Safe Harbor Rule Is the Clearest Regulatory Tailwind Coinbase Has Seen in YearsyesterdayDEFENSEThe Refueling Line Nobody Prices Into BWXT4 weeks agoDEFENSENATO's 3.5% GDP Spending Push Sends a Long-Term Revenue Signal to Raytheon, Lockheed, and NorthropyesterdayDEFENSEThe Law That Guarantees Matson a Buyer, No Matter the Price4 weeks agoHEALTHCARE & FDAMedicare Covering Obesity Drugs for the First Time Is a Direct Volume Catalyst for Novo Nordisk and Eli LillyyesterdayENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers4 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program as State-Level Momentum Builds — Constellation, Vistra, and Oklo Are the Plays4 days agoTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two4 weeks agoENERGYU.S.-Iran Initial Deal Eases Sanctions Pressure — Oil Prices Face a Ceiling, E&P Stocks Feel It4 days agoDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat4 weeks agoDEFENSENATO's 'Report Card' Pressure Means Years of European Defense Spending — RTX and Lockheed Are the First Calls4 days agoENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom4 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Obesity Drugs — Novo Nordisk and Eli Lilly Are the Direct Winners4 days agoDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch4 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Market4 days agoDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes3 weeks agoCRYPTOSEC Commissioner Signals Crypto Clarity Act Could Pass This Summer — Coinbase and Robinhood Are the Clearest Beneficiaries4 days agoDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization3 weeks agoTECHWhite House Lifts Export Controls on Anthropic's Advanced AI Models — Nvidia and AMD Are the Coattail Trade4 days agoENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear3 weeks agoDEFENSENATO's Spending Surge Is Real — and the US Defense Primes Are the Ones Getting Paid5 days agoENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Children as Young as 2, Widening the Market for Vertex and CRISPR Therapeutics5 days agoDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop3 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Payday for AeroVironment5 days agoENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade3 weeks agoDEFENSEThe US-Iran Ceasefire Deal Pressures Oil Prices — and Reshuffles the Defense Trade5 days agoDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One3 weeks agoTECHTrump's Quantum Computing Executive Orders Create a Policy Tailwind for a Handful of Public Names5 days agoDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money3 weeks agoCRYPTOCrypto Clarity Act Progress and SEC's ETF Rule Review Are the Two Biggest Near-Term Catalysts for Coinbase and Robinhood5 days agoENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors3 weeks agoTRADE & TARIFFSNike's Tariff Refund Windfall Shows How Import-Heavy Brands Can Turn Trade Policy Into a Margin Story6 days agoENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus3 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program, Adding Momentum to the SMR Buildout Trade6 days agoDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AI3 weeks agoHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Users on Notice — and Creates an Opening for Clean-Label Suppliers6 days agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alive3 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment6 days agoDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Prime3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market6 days agoDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spending3 weeks agoTECHTrump's Post-Quantum Cryptography Executive Order Creates a Compliance Spending Mandate — and Clear Beneficiaries6 days agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hub3 weeks agoHEALTHCARE & FDAMedicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New Payerlast weekDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washington3 weeks agoTECHCommerce Department's AI Model Export Controls Are the Next Nvidia Headwind — and AMD Isn't Immunelast weekENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economics3 weeks agoDEFENSEHegseth's NATO Broadside and European Force Review Put Defense Primes in a Complicated Spotlast weekENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deduction3 weeks agoCRYPTOBitcoin Is Down 33% at Mid-Year and ETF Outflows Hit $4.3B in June — Coinbase and the Miners Are Feeling Itlast weekDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Bet3 weeks agoENERGYWashington Is Rewriting Nuclear Radiation Safety Rules — Constellation, Vistra, and the SMR Crowd All Winlast weekDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratos3 weeks agoENERGYThe US-Iran Initial Deal Puts Sanction Relief on the Table — and That's a Headwind for Oil Prices and E&P Stockslast weekENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keys3 weeks agoWHITE HOUSETrump's Quantum Executive Order Sets a Hard Deadline — and Quantum Computing Stocks Are the Immediate Beneficiarylast weekDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguise3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger Marketlast weekDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Story2 weeks agoTRADE & TARIFFSNike's Tariff Refunds Are a One-Time Boost, Not a Structural Fix — Here's What the Q4 Beat Actually Meanslast weekENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Gift2 weeks agoWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity Stacklast weekENERGYThe BLM Calendar That Moves COP and OXY2 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its Rivalslast weekDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Through2 weeks agoDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's Expenselast weekDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivot2 weeks agoCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most Risklast weekENERGYLNG Export Licenses: How a FERC Approval Mints a Monopoly2 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customerslast weekDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differently2 weeks agoDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending Boomlast weekENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oil2 weeks agoDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets Paidlast weekDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenly2 weeks agoWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet Tailwindlast weekDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes2 weeks agoMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big Techlast weekDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program2 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is Movinglast weekDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Order2 weeks agoTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real Moneylast weekDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machine2 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Marketlast weekDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own Itlast weekDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company Foreverlast weekDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sideslast weekDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stocklast weekDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Streamlast weekTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watchlast weekDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligationlast weekMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Politicallast weekDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTXlast weekTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producerslast weekDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Betlast weekDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spendinglast weekDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Tradelast weekDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Gamelast weekDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risklast week
1 free article left this week. A free account gets you 4 a week.Go Pro →
Trade & Tariffs

McCormick's $28M Tariff Refund Is a One-Time Cushion — the Underlying Cost Pressure Hasn't Gone Away

A tariff refund helps McCormick's near-term margins, but the Iran conflict and broader spice import costs signal ongoing input inflation for food companies.

Image: Money Racket
By at Money Racket · Jul 11, 2026

McCormick & Company received a $28 million tariff refund while simultaneously flagging that the Iran conflict is raising input costs. The refund provides a near-term margin benefit, but the company's commentary points to continued commodity and tariff-driven cost pressure in its supply chain.

Who cashes in: McCormick (MKC) gets the direct cash benefit — $28 million against a company with roughly $700 million in annual operating income is meaningful but not transformative. The more important signal is that tariff exclusion requests and refund processes are working, which is a modest positive for other food companies with pending exclusion requests. Sysco (SYY) and US Foods (USFD), as large food distributors, benefit when their supplier input costs stabilize.

A $28 million refund is real money, but McCormick is telling you in the same breath that the cost environment is getting harder — not easier.

Who's exposed: The Iran conflict cost signal is the more important story for the sector. Spices, herbs, and specialty ingredients sourced from the Middle East and South Asia face supply disruption risk. Smaller specialty food companies without McCormick's scale to absorb or pass through cost increases are more vulnerable. PepsiCo (PEP) separately flagged tariff refund benefits to its CFO, suggesting the refund dynamic is broader — but so is the underlying cost pressure. Companies with heavy reliance on imported food ingredients and limited pricing power (private-label competitors, smaller branded food names) face the most margin squeeze.

What to watch next: Whether the Iran conflict escalates to the point of disrupting shipping lanes or specific ingredient supply chains. Also watch for the next round of tariff exclusion decisions from USTR — food companies have been active filers, and the outcome of those requests sets the cost baseline for the back half of 2026.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →